TY - JOUR
T1 - Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners
AU - Kamarulzaman, Adeeba
AU - Reid, Stewart E.
AU - Schwitters, Amee
AU - Wiessing, Lucas
AU - El-Bassel, Nabila
AU - Dolan, Kate
AU - Moazen, Babak
AU - Wirtz, Andrea L.
AU - Verster, Annette
AU - Altice, Frederick L.
N1 - Funding Information:
AK has received funding from the University of Malaya High Impact Research Grant (HIRGA E000001–20001). FLA has received speaker fees from Bristol-Myers Squibb, Gilead, Merck Sharp & Dohme; and has received research support grants from Gilead Foundation and the Elton John AIDS Foundation. The remaining authors declare no competing interests.
Funding Information:
This paper and The Lancet Series on HIV and related infections in prisoners were supported by grants to the Center for Public Health and Human Rights at John Hopkins Bloomberg School of Public Health from: National Institute on Drug Abuse ( R01DA025943, R01DA029910, R01DA030768, R01DA030762, R01DA033679, R01AA018944, and K24DA017072 for FLA ); the Open Society Foundations; the UN Populations Fund; and the John Hopkins University Center for AIDS Research, a programme funded by the National Institute Health ( P30AOI094189 ). We thank Sahar Saeedi Moghaddam for contributing to preparation of figure 2 , Ehab Salah and Fabienne Hariga for providing data on coverage of interventions, and thank Awoniyi Awofeso for providing consent to reproduce figure 1 . AS and AV are staff members of WHO. We are responsible for the views expressed in this Series paper, and they do not necessarily represent the decisions, policy, or views of WHO.
Publisher Copyright:
© 2016 Elsevier Ltd
PY - 2016/9/10
Y1 - 2016/9/10
N2 - The prevalence of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis are higher in prisons than in the general population in most countries worldwide. Prisons have emerged as a risk environment for these infections to be further concentrated, amplified, and then transmitted to the community after prisoners are released. In the absence of alternatives to incarceration, prisons and detention facilities could be leveraged to promote primary and secondary prevention strategies for these infections to improve prisoners health and reduce risk throughout incarceration and on release. Effective treatment of opioid use disorders with opioid agonist therapies (eg, methadone and buprenorphine) prevents blood-borne infections via reductions in injection in prison and after release. However, large gaps exist in the implementation of these strategies across all regions. Collaboration between the criminal justice and public health systems will be required for successful implementation of these strategies.
AB - The prevalence of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis are higher in prisons than in the general population in most countries worldwide. Prisons have emerged as a risk environment for these infections to be further concentrated, amplified, and then transmitted to the community after prisoners are released. In the absence of alternatives to incarceration, prisons and detention facilities could be leveraged to promote primary and secondary prevention strategies for these infections to improve prisoners health and reduce risk throughout incarceration and on release. Effective treatment of opioid use disorders with opioid agonist therapies (eg, methadone and buprenorphine) prevents blood-borne infections via reductions in injection in prison and after release. However, large gaps exist in the implementation of these strategies across all regions. Collaboration between the criminal justice and public health systems will be required for successful implementation of these strategies.
UR - http://www.scopus.com/inward/record.url?scp=84986247449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84986247449&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(16)30769-3
DO - 10.1016/S0140-6736(16)30769-3
M3 - Review article
C2 - 27427456
AN - SCOPUS:84986247449
SN - 0140-6736
VL - 388
SP - 1115
EP - 1126
JO - The Lancet
JF - The Lancet
IS - 10049
ER -